The exposure of highly toxic aconitine does not significantly impact the activity and expression of cytochrome P450 3A in rats determined by a novel ultra performance liquid chromatography-tandem mass spectrometric method of a specific probe buspirone

Food and Chemical Toxicology

Volumn 51, Issue 1, 2013, Pages 396-403

  Zhu, Lijun ^a   Yang, Xiaoshan ^a   Zhou, Juan ^a   Tang, Lan ^a   Xia, Bijun ^a   Hu, Ming ^a,b   Zhou, Fuyuan ^a   Liu, Zhongqiu ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Aconitine; Buspirone; CYP3A; Drug drug interaction; UPLC MS MS

Indexed keywords

1 (2 PYRIMIDINYL)PIPERAZINE; 6' HYDROXYBUSPIRONE; ACONITINE; BUSPIRONE; CYTOCHROME P450 3A; DRUG METABOLITE; UNCLASSIFIED DRUG;

ACONITE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY; LIVER MICROSOME; MALE; MOLECULAR PROBE; NONHUMAN; PHARMACOKINETICS; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING;

ACONITINE; ACONITUM; ADMINISTRATION, ORAL; ANIMALS; BUSPIRONE; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; LIVER; MALE; MEDICINE, CHINESE TRADITIONAL; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

ACONITUM; RATTUS;

EID: 84869121046     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.10.008     Document Type: Article

References (36)

1. Backman J.T., Mäenpää J., Belle D.J., Wrighton S.A., Kivistö K.T., Neuvonen P.J. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin. Pharmacol. Ther. 2000, 67:382-390.
2. Benmebarek M., Devaud C., Gex-Fabry M., Powell Golay K., Brogli C., Baumann P., Gravier B., Eap C.B. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin. Pharmacol. Ther. 2004, 76:55-63.
3. Burk O., Wojnowski L. Cytochrome P450 3A and their regulation. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 369:105-124.
4. Capasso F. Phytotherapy: A Quick Reference to Herbal Medicine 2003, Springer Verlag.
5. Chen J., Halls S.C., Alfaro J.F., Zhou Z., Hu M. Potential beneficial metabolic interactions between tamoxifen and isoflavones via cytochrome P450-mediated pathways in female rat liver microsomes. Pharm. Res. 2004, 21:2095-2104.
6. Chen J., Lin H., Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmacol. Exp. Ther. 2003, 304:1228-1235.
7. Dong N.N., Wang M.Y. Progress of cytochrome P450 in the treatment of tumors. Chin. J. Gerontol. 2009, 29:2686-2689.
8. Ernst E., Pittler M.H., Stevinson C., White A. The desktop guide to complementary and alternative medicine: an evidence-based approach. J. R. Soc. Med. 2001, 94:650-651.
9. Ernst E., Pittler M.H., Wider B., Boddy K. Oxford Handbook of Complementary Medicine 2008, Oxford University Press.
10. FDA, 2006. Drug Administration Guidance for Industry: Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Recommendations [online]. Available from: http://www.fda.gov/cder.
11. Gammans R.E., Mayol R.F., Labudde J.A. Metabolism and disposition of buspirone. Am. J. Med. 1986, 80:41-51.
12. Gu X., Lu Y., Su X. The influence of Gancao-Fuzi decoction on anti-freeradical action in rheumatoid arthritis mice. Zhongguo Minzu Minjian Yiyao 2008, 17. 19-20, 32.
13. Hu C.M., Li Y., Xu S.Y. Progress in polymorphic drug-metabolizing enzymes of NSAIDs. Anhui Med. Pharm. J. 2002, 6:3-6.
14. Izzo A.A., Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs 2009, 69:1777-1798.
15. Jajoo H.K., Mayol R., LaBudde J.A., Blair I. Metabolism of the antianxiety drug buspirone in the rat. Drug Metab. Dispos. 1989, 17:625-633.
16. Laine K., Ahokoski O., Huupponen R., Hänninen J., Palovaara S., Ruuskanen J., Björklund H., Anttila M., Rouru J. Effect of the novel anxiolytic drug deramciclane on the pharmacokinetics and pharmacodynamics of the CYP3A4 probe drug buspirone. Eur. J. Clin. Pharmacol. 2003, 59:761-766.
17. Lamberg T.S., Kivistö K.T., Laitila J., Mårtensson K., Neuvonen P.J. The effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of buspirone. Eur. J. Clin. Pharmacol. 1998, 54:761-766.
18. Li J., Qian L., Lv Q.Z. Interactions related to cytochrome P450 enzymes among cardiovascular drugs. China Pharm. 2006, 17:1179-1181.
19. Li X.S., Cao X.Y., Wu S.Q., Deng W.H. Study on the resources of Aconitum carmichacli Debx. & its development and utilization in HanZhong. Chin. Acad. Med. Mag. Organ. 2002, 3:55-57.
20. Martignoni M., Groothuis G.M.M., De Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin. Drug Metab. Toxicol. 2006, 2:875-894.
21. Mizugaki M., Ito K., Ohyama Y., Konishi Y., Tanaka S., Kurasawa K. Quantitative analysis of Aconitum alkaloids in the urine and serum of a male attempting suicide by oral intake of aconite extract. J. Anal. Toxicol. 1998, 22:336-340.
22. Saxena A., Tripathi K.P., Roy S., Khan F., Sharma A. Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 2008, 3:198-204.
23. Singhuber J., Zhu M., Prinz S., Kopp B. Aconitum in traditional Chinese medicine - A valuable drug or an unpredictable risk?. J. Ethnopharmacol. 2009, 126:18-30.
24. Song L., Hong X., Ding X. Modern Dictionary of Chinese Materia Medica 2001, People's Medical Publishing House, Beijing, pp. 146-147.
25. Sugiyama M., Fujita K., Murayama N., Akiyama Y., Yamazaki H., Sasaki Y. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation. Drug Metab. Dispos. 2011, 39:757-762.
26. Tang L., Ye L., Lv C., Zheng Z., Gong Y., Liu Z. Involvement of CYP3A4 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol. Lett. 2011, 202:47-54.
27. Wada K., Nihira M., Hayakawa H., Tomita Y., Hayashida M., Ohno Y. Effects of long-term administrations of aconitine on electrocardiogram and tissue concentrations of aconitine and its metabolites in mice. Forensic Sci. Int. 2005, 148:21-29.
28. Wang Y., Wang S., Liu Y., Yan L., Dou G., Gao Y. Characterization of metabolites and cytochrome P450 isoforms involved in the microsomal metabolism of aconitine. J. Chromatogr. B 2006, 844:292-300.
29. Wang Y.Y., Lu Z.L. Advanced Textbook of Internal Medicine of TCM (Zhongyi Neikexue Gaoji Congshu) 1999, People's Medical Publishing House, Beijing, pp. 912-963.
30. Weaver R. Assessment of drug-drug interactions: concepts and approaches. Xenobiotica 2001, 31:499-538.
31. Yamada H., Nakamura T., Oguri K. Induction of rat hepatic cytochromes P450 by toxic ingredients in plants: lack of correlation between toxicity and inductive activity. J. Toxicol. Sci. 1998, 23:395-402.
32. Ye L., Tang L., Gong Y., Lv C., Zheng Z., Jiang Z., Liu Z. Characterization of metabolites and human P450 isoforms involved in the microsomal metabolism of mesaconitine. Xenobiotica 2011, 41:46-58.
33. Ye L., Wang T., Yang C., Tang L., Zhou J., Lv C., Gong Y., Jiang Z., Liu Z. Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol. Lett. 2011, 204:81-91.
34. Yocca F. Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors. J. Clin. Psychopharm. 1990, 10:6S-12S.
35. Zhou Y.P., Liu W.H., Zeng G.Y., Chen D.H., Li H.Y., Song W.L. The toxicity of aconitine and its analogs and their effects on cardiac contractile function. Yaoxue Xuebao 1984, 19:641-646.
36. Zhu M., Zhao W., Jimenez H., Zhang D., Yeola S., Dai R., Vachharajani N., Mitroka J. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab. Dispos. 2005, 33:500-507.